NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine and to perform restorative and fusion procedures in a minimally-disruptive fashion. Its biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty, which are used for spinal fusion or bone healing process. The company's IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. It also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, the company offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. NuVasive, Inc. sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:NUVA
CUSIP67070410
Phone858-909-1800
Debt
Debt-to-Equity RatioN/A
Current Ratio2.80
Quick Ratio1.53
Price-To-Earnings
Trailing P/E Ratio35.23
Forward P/E Ratio28.93
P/E Growth1.77
Sales & Book Value
Annual Sales$1.03 billion
Price / Sales3.45
Cash Flow$5.0771 per share
Price / Cash13.62
Book Value$15.68 per share
Price / Book4.41
Profitability
EPS (Most Recent Fiscal Year)$1.91
Net Income$83 million
Net Margins3.96%
Return on Equity13.70%
Return on Assets6.43%
Miscellaneous
Employees2,600
Outstanding Shares51,420,000
Market Cap$3.32 billion
NuVasive (NASDAQ:NUVA) Frequently Asked Questions
What is NuVasive's stock symbol?
NuVasive trades on the NASDAQ under the ticker symbol "NUVA."
How will NuVasive's stock buyback program work?
NuVasive declared that its board has authorized a stock buyback plan on Wednesday, October 25th 2017, which authorizes the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company's board believes its shares are undervalued.
How were NuVasive's earnings last quarter?
NuVasive, Inc. (NASDAQ:NUVA) issued its quarterly earnings data on Tuesday, July, 31st. The medical device company reported $0.58 earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of $0.58. The medical device company had revenue of $281.56 million for the quarter, compared to the consensus estimate of $276.05 million. NuVasive had a return on equity of 13.70% and a net margin of 3.96%. View NuVasive's Earnings History.
When is NuVasive's next earnings date?
What guidance has NuVasive issued on next quarter's earnings?
NuVasive issued an update on its FY18 earnings guidance on Tuesday, July, 31st. The company provided EPS guidance of $2.37-2.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.44. The company issued revenue guidance of $1.095-1.105 billion, compared to the consensus revenue estimate of $1.10 billion.
What price target have analysts set for NUVA?
18 brokers have issued 12 month price targets for NuVasive's stock. Their forecasts range from $47.00 to $79.00. On average, they expect NuVasive's share price to reach $64.6875 in the next year. This suggests that the stock has a possible downside of 4.7%. View Analyst Price Targets for NuVasive.
What is the consensus analysts' recommendation for NuVasive?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 8 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NuVasive.
What are Wall Street analysts saying about NuVasive stock?
Here are some recent quotes from research analysts about NuVasive stock:
- 1. Cantor Fitzgerald analysts commented, ": We maintain our Neutral rating on NUVA, but raise our PT to $58 from $54, as we see less downside risk to the stock than what we thought heading into 2Q. Although we are encouraged by the better-than-expected organic top-line growth in 2Q, we note that it is only one quarter. That said, NUVA’s 2H comps are significantly easier, particularly in the US, and suggest that NUVA could sustain organic growth at its 2Q level in 2H. NUVA’s guidance implies 2H organic growth of 6%+, a meaningful step up from 1H (+3%). Given the repeated delays in realizing GM improvement from the West Carrollton facility, we continue to see risk in NUVA’s ability to deliver on its 2018 operating margin guidance (OM)." (7/31/2018)
- 2. According to Zacks Investment Research, "NuVasive has underperformed its industry over the past six months. We note that, the company saw softness in U.S. Spinal Hardware and U.S. Surgical Support businesses in the last reported quarter. Headwinds like Margin drag, pricing pressure, reimbursement issues and competitive landscape are major downsides. However, the international business registering more than 20% growth for the sixth consecutive quarter buoys optimism. Further, efforts like the addition of Lateral Single-Position Surgery to expand its lateral procedural solutions offerings will help the company rebound in the rest of the year. The company also expects to see a 400 bps improvement in gross margins on increasing production in its Ohio manufacturing facility in the second half of 2018. Moreover, we are upbeat about the integration synergy of recently-completed buyout of SafePassage." (7/3/2018)
- 3. Needham & Company LLC analysts commented, "NUVA’s 1Q18 revenue beat and EPS missed consensus. Management reiterated its 2018 revenue and EPS guidance. Organic revenue growth improved to 2% in 1Q18 from 0% in 4Q17 as US Spinal Hardware and biologics growth improved. NUVA’s revenue guidance requires it to accelerate its revenue growth; we believe that it can do this given new products, easing comps, and stabilization of biologics. And its EPS guidance requires a substantial improvement in its gross and operating margin; we believe it can do this with improvements in its new manufacturing plant and SG&A leverage. Unfortunately, both the revenue and margin ramps are likely to continue to make NUVA a show me" story despite its discount P/E multiple." (5/2/2018)
Who are some of NuVasive's key competitors?
Some companies that are related to NuVasive include DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), ICU Medical (ICUI), Integra Lifesciences (IART), Haemonetics (HAE), Globus Medical (GMED), Insulet (PODD), Penumbra (PEN), Cantel Medical (CMD), Novocure (NVCR), Merit Medical Systems (MMSI), Irhythm Technologies (IRTC), Nevro (NVRO) and Tandem Diabetes Care (TNDM).
Who are NuVasive's key executives?
NuVasive's management team includes the folowing people:
- Mr. Gregory T. Lucier, Chairman & CEO (Age 54)
- Mr. Rajesh J. Asarpota, Exec. VP & CFO (Age 51)
- Mr. Matthew W. Link, Exec. VP of Strategy, Technology & Corp. Devel. (Age 43)
- Dr. Peter M. Leddy, Exec. VP of People & Culture (Age 55)
- Mr. Harry Skip Kiil, Exec. VP of Global Commercial (Age 43)
Has NuVasive been receiving favorable news coverage?
Media stories about NUVA stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NuVasive earned a coverage optimism score of 0.19 on Accern's scale. They also assigned media headlines about the medical device company an impact score of 46.25 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for NuVasive.
Who are NuVasive's major shareholders?
NuVasive's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (4.06%), Dimensional Fund Advisors LP (2.53%), Eagle Asset Management Inc. (2.47%), Fisher Asset Management LLC (2.47%), Anchor Capital Advisors LLC (1.91%) and Hood River Capital Management LLC (1.69%). Company insiders that own NuVasive stock include Gregory T Lucier, Jason Hannon, Joan Stafslien, Lesley H Howe, Matthew Link, Michael D Ohalleran, Patrick Miles and Peter Michael Leddy. View Institutional Ownership Trends for NuVasive.
Which major investors are selling NuVasive stock?
NUVA stock was sold by a variety of institutional investors in the last quarter, including Wolverine Asset Management LLC, OppenheimerFunds Inc., Janus Henderson Group PLC, SG Capital Management LLC, Victory Capital Management Inc., Massachusetts Financial Services Co. MA, Bank of Montreal Can and Advisors Asset Management Inc.. View Insider Buying and Selling for NuVasive.
Which major investors are buying NuVasive stock?
NUVA stock was purchased by a variety of institutional investors in the last quarter, including Anchor Capital Advisors LLC, Hood River Capital Management LLC, Glenmede Trust Co. NA, Eagle Asset Management Inc., Marshall Wace LLP, Point72 Asset Management L.P., Motley Fool Wealth Management LLC and Dimensional Fund Advisors LP. Company insiders that have bought NuVasive stock in the last two years include Gregory T Lucier, Joan Stafslien, Michael D Ohalleran, Patrick Miles and Peter Michael Leddy. View Insider Buying and Selling for NuVasive.
How do I buy shares of NuVasive?
Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NuVasive's stock price today?
One share of NUVA stock can currently be purchased for approximately $67.90.
How big of a company is NuVasive?
NuVasive has a market capitalization of $3.32 billion and generates $1.03 billion in revenue each year. The medical device company earns $83 million in net income (profit) each year or $1.91 on an earnings per share basis. NuVasive employs 2,600 workers across the globe.
How can I contact NuVasive?
NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]
MarketBeat Community Rating for NuVasive (NASDAQ NUVA)
MarketBeat's community ratings are surveys of what our community members think about NuVasive and other stocks. Vote "Outperform" if you believe NUVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NUVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
